UBS AG has announced the filing of a pricing supplement for its Trigger Autocallable Contingent Yield Notes, linked to the common stock of Credo Technology Group Holding Ltd. This offering, which totals $625,000, is set to mature on November 15, 2029. The notes will provide contingent coupons based on the performance of the underlying asset, reflecting UBS's commitment to offering innovative financial products.
This move is significant for UBS as it expands its product offerings in the competitive landscape of national commercial banks. The introduction of these notes indicates UBS's strategy to cater to investors looking for higher yields, despite the inherent risks associated with such instruments.
Background
UBS AG, a prominent player in the financial services sector, is classified under the SIC code 6021, which pertains to National Commercial Banks. The company is listed on the New York Stock Exchange under multiple tickers, including AMUB and BDCX. As of November 13, 2026, UBS filed several documents, including this pricing supplement, to enhance its service offerings.
What the Filing Says
The SEC filing details the structure of the Trigger Autocallable Contingent Yield Notes, which are described as unsubordinated, unsecured debt obligations. The notes will pay a contingent coupon only if the closing level of the underlying asset meets certain criteria on specified observation dates. If the asset does not meet these criteria, no coupon will be paid for that period.
Impact
This offering may attract a diverse range of investors, particularly those looking for higher yield opportunities in a low-interest-rate environment. However, potential buyers should be aware of the significant risks, including the possibility of losing their initial investment if the underlying asset underperforms.
What's Next
The filing does not specify what happens next, but it indicates that the notes will be available for trading following their issuance, with the initial trade date set for November 12, 2026, and a settlement date of November 17, 2026.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










